Brief: Vincerx Says First Patient Dosed In Phase 1B Study Of VIP152 In MYC-Driven Relapsed Or Refractory Aggressive Lymphomas, Advanced Solid Tumors
03/06/2021 23:15
June 3 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B
STUDY
OF VIP152 IN MYC-DRIVEN RELAPSED OR REFRACTORY AGGRESSIVE
LYMPHOMAS AND ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX1SLDZ4
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign